Funding Wizard

This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the ?participating NIH Institutes or Centers. This program is intended to support New Investigators and At-Risk Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences.Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIHs Interest in Diversity), are eligible to apply. Investigators from categories A and B are particularly encouraged to work with their institutions to apply

This Funding Opportunity Announcement (FOA) solicits applications for team-centric development and validation of innovative non-invasive imaging technologies that could have a transformative impact on the study of brain function/connectivity. Applications are expected to turn a novel concept into a functional prototype using this phased grant mechanism. The feasibility should be established by the end of its first phase and serve as a foundation for the transition to its second phase. Fully developing the technology into a functional prototype and validating it by in-vivo animal or human function/connectivity imaging are anticipated in the second phase. The research plan should provide a realistic timeline and tangible milestones to support the proposed development effort. Awards will be integrated into the BRAIN Non-Invasive Imaging Consortium, as a coordinated network on brain function/connectivity imaging.

This Funding Opportunity Announcement (FOA) solicits applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.

The ORWH and participating organizations and institutes seek applications for Specialized Centers of Research Excellence (SCORE) on Sex Differences. The Centers of Excellence will support interdisciplinary approaches to advance translational research on sex differences. Each SCORE institution should develop a research agenda bridging basic and clinical research underlying a health issue that is pertinent to improving the health of women.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for a Laboratory Core for the Environmental influences on Child Health Outcomes (ECHO) program. The ECHO Laboratory Core will provide leadership, project management, and infrastructure for all activities related to ECHO Cohort biospecimens and data generated from biospecimen assays. The main roles of the ECHO Laboratory Core are to: (1) facilitate ECHO Cohort biospecimen collection and processing; (2) manage the ECHO Cohort Biorepository; (3) perform or facilitate a wide range of biospecimen assays to support ECHO Cohort analyses; and (4) coordinate biospecimen information and assay results. This FOA runs in parallel with companion FOAs that solicit applications for Cohort Study Sites for follow-up of existing ECHO Cohort participants and for recruitment of new pregnant participants (RFA XXXX), for Cohort Study Sites only for follow-up of existing ECHO Cohort participants (RFA XXXX), for Cohort Study Sites only for recruitment of new pregnant participants (RFA XXXX), for an ECHO Coordinating Center (RFA XXXX), for an ECHO Data Analysis Center (RFA XXXX), and for an ECHO Measurement Core (RFA XXXX).

This Funding Opportunity Announcement (FOA) intends to support a group of Specialized Collaboratories that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to create comprehensive and highly granular brain cell atlases in human, non-human primates, and mouse, in coordination and collaboration with other BICAN projects. In particular, the Specialized Collaboratories are expected to complement the Comprehensive Centers in BICAN with distinct capabilities, competencies, and research aims. The overarching goal of the BICAN is to build reference brain cell atlases that will be widely used throughout the research community, providing a molecular and anatomical foundational framework for the study of brain function and disorders.

Authority: Public Law 99-591 (43 U.S.C. § 36(c)), the USGS Organic Act of March 3, 1879, as amended (43 U.S.C. § 31 et seq.), 16 U.S.C. § 1(a)(2)(j), 16 U.S.C. § 1(g), 16 U.S.C. § 5933, and 16 U.S.C. § 753(a) Catalog of Federal Domestic Assistance (CFDA) Number 15.808

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NCI R25 program is to support research and educational activities that enhance the diversity of the cancer biomedical workforce. We seek to do this by providing training navigation to support scholars from diverse backgrounds, including individuals from groups shown to be underrepresented in the cancer biomedical workforce. The TEAM program will pilot test the use of training champions (TCs) at minority serving institutions (MSIs) to support the development of educational activities and scientific career development programs to enhance the preparation, productivity and progress of scholars from diverse backgrounds, including those from underrepresented racial and ethnic groups, in the Notice of NIH's Interest in Diversity, NOT-OD-20-031. The career development levels of focus for this FOA will include predoctoral and postdoctoral fellows, and early-stage investigators (ESIs). TCs are defined as personnel located within the MSI who can assist potential applicants with their plans to apply, attain, or transition to an independent grant award. This RFA will leverage TCs to assist scholars in identifying funding opportunities, networking with appropriate NCI/NIH program directors, and locating resources for competitive application preparation. TCs will also provide additional training support, navigation, and resources to enhance the skills required to successfully identify, prepare, submit, and obtain grants and career development opportunities. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Mentoring Activities.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

The purpose of this funding opportunity announcement (FOA) is to establish Centers to support research that will accelerate the translational use of Microphysiological Systems (MPS) in drug development through regulatory acceptance and adoption for industrial use, by establishing MPS that are fit-for-purpose for industry needs and have specific defined contexts of use (CoUs) and will be developed with consideration of applicable expectations to achieve regulatory approval. For this FOA, the term drugs refers to both human pharmacological and biological products unless otherwise specified. These Centers will further the development of MPS as drug development tools (DDTs) that, once qualified, will be made publicly and commercially available to fill unmet needs in drug development.